MENUMENU
  • Covid Clear
  • Services
        • Human challenge full-service solution
        • human challenge full service solution

          Industry leading provider of viral challenge studies

          • See Our Solution
        • hVIVO Challenge Models
          • Influenza
          • RSV
          • HRV
          • Asthma
          • COPD
          • Cough
        • Laboratory Services
          • Virology
          • Immunology
          • Biomarkers
  • News, Media & Events

        • News, Media & Events

          A source for the latest press releases, scientific publications and other media as well as details of investor and scientific events that we attend and host across the world.

        • Media Coverage
        • Company News
        • Videos
        • Events
  • About Us

        • About Us

          An industry leading services provider in viral challenge studies and laboratory services supporting product development for customers developing antivirals, vaccines and respiratory therapeutics.

          • More about hVIVO
        • Overview
        • Executive Leadership Team
        • Scientific Papers / Abstracts
        • Quality Commitment
        • Ethics & Compliance
        • img

          LATEST PRESS RELEASE

          06.08.19 hVIVO Successfully Completes RSV Challenge Study in Older Adults

        • UPCOMING EVENTS

          IABS, International Alliance for Biological Standardization06 Feb - 07 Feb, Oxford, United Kingdom
  • Volunteers
  • Careers
  • Contact Us

Influenza Vaccine May Protect Against Guillain-Barre Syndrome

January 16, 2015 4:54 pm

https://www.medscape.com/viewarticle/838208

Posted by Rob LW

Follow @hVIVO_UK

Comments are closed here.

Whether you’re a potential customer, job seeker, health professional or an investor, you can find the best way to contact us from the list below.

Contact Us
  • Terms & Conditions
  • Careers
  • Sitemap
© 2020 Copyright hVIVO Services Limited. All rights reserved. hVIVO Services Limited (“hVIVO”) is registered in England and Wales with registration number 02326557 and registered office at Queen Mary BioEnterprises Innovation Centre, 42 New Road, London, E1 2AX, UK.
Privacy Policy | Cookie Policy